University of Iowa Research Foundation

The United States Government As Represented by the Department of Veterans Affairs

American Biogenetic Sciences, Inc.

James H McLinden

Jack T Stapleton

Jinhua Xiang

Nirjal Bhattarai

Donna Klinzman

Elliot D Rosen

Bev Davidson

Patricia L Winokur

Jinhau Xiang

Qing Chang

The disclosure provides compositions and methods involving viral RNA segments for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations.

Viral RNA segments as immunomodulatory agents and vaccine components

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.

Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.

GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent

Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.

Flavivirus NS5A proteins for the treatment of HIV

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.

The present invention is directed to genetically engineered expression systems which encode a recombinant Hepatitis A virus (HAV) proteins capable of forming capsid particles. By way of example baculovirus vectors were utilized in order to express recombinant HAV proteins. The recombinant baculoviruses of the invention are formed by replacing regions of the polyhedrin structural gene coding sequences with HAV DNA by recombinant DNA techniques. Additionally, the polyhedrin transcriptional initiation site is altered in these recombinant baculoviruses such that only HAV proteins and not polyhedrin protein sequences are expressed from the polyhedrin promoter. The recombinant HAV capsid particles produced in accordance with the present invention can be particularly useful as vaccines.

Growing community of inventors

Mishawaka, IN, United States of America

James H McLinden